This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meijers-Heijboer, H. Articles by Klijn, J. G.M. Search for Related Content PubMed PubMed Citation Articles by Meijers-Heijboer, H. Articles by Klijn, J. G.M.

Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation

From the Rotterdam Family Cancer Clinic, Department of Clinical Genetics; and Department of Medical Oncology, Department of Surgical Oncology, and Department of Gynecology, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.

Address reprint requests to J.G.M. Klijn, MD, Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus MC Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands; email: j.g.m.klijn{at}erasmusmc.nl.

Purpose: To analyze the use of genetic testing, prophylactic mastectomy, and oophorectomy among women with breast and/or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Patients and Methods: We examined prospectively the use of BRCA1/BRCA2 testing in all women with a primary breast or ovarian cancer from a consecutive series of 112 high-risk families in which a BRCA1/BRCA2 mutation eventually was identified. The rate of prophylactic bilateral and contralateral mastectomy and prophylactic oophorectomy was analyzed in the women who carried a BRCA1/BRCA2 mutation and who had no metastatic disease at the time of the genetic test disclosure. We examined predictors for genetic test uptake and prophylactic surgery using univariate and multivariate analysis.

Results: Overall, 192 of 220 women (87%) with primary tumors underwent genetic testing. Eleven of these 192 tested women (6%) appeared not to carry the family-specific BRCA1/BRCA2 mutation. Genetic testing occurred significantly more frequently at ages younger than 50 years (P = .04) and in persons with multiple primary tumors (P = .02). Among eligible women, 35 of 101 (35%) requested bilateral or contralateral mastectomy, and 47 of 95 (49%) requested oophorectomy. Women aged younger than 50 years and women who developed their first tumor after the initial identification of a BRCA1/BRCA2 mutation in the family were significantly (both P = .01) more likely to opt for prophylactic bilateral or contralateral mastectomy.

Conclusion: In a clinical setting, we show a high demand for BRCA1/BRCA2 testing and for prophylactic surgery by women with breast and/or ovarian cancer from high-risk families.

This article has been cited by other articles:

				B. A. M. Heemskerk-Gerritsen, C. T. M. Brekelmans, M. B. E. Menke-Pluymers, A. N. van Geel, M. M. A. Tilanus-Linthorst, C. C. M. Bartels, M. Tan, H. E. J. Meijers-Heijboer, J. G. M. Klijn, and C. Seynaeve Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic Ann. Surg. Oncol., December 1, 2007; 14(12): 3335 - 3344. [Abstract] [Full Text] [PDF]

				A. Soran, J. Falk, M. Bonaventura, D. Keenan, G. Ahrendt, and R. Johnson Is Routine Sentinel Lymph Node Biopsy Indicated in Women Undergoing Contralateral Prophylactic Mastectomy? Magee-Womens Hospital Experience Ann. Surg. Oncol., February 1, 2007; 14(2): 646 - 651. [Abstract] [Full Text] [PDF]

				J. B. Madalinska, M. van Beurden, E. M.A. Bleiker, H. B. Valdimarsdottir, L. Lubsen-Brandsma, L. F. Massuger, M. J.E. Mourits, K. N. Gaarenstroom, E. B.L. van Dorst, H. van der Putten, et al. Predictors of Prophylactic Bilateral Salpingo-Oophorectomy Compared With Gynecologic Screening Use in BRCA1/2 Mutation Carriers J. Clin. Oncol., January 20, 2007; 25(3): 301 - 307. [Abstract] [Full Text] [PDF]

				K. Anderson, J. S. Jacobson, D. F. Heitjan, J. G. Zivin, D. Hershman, A. I. Neugut, and V. R. Grann Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med, March 21, 2006; 144(6): 397 - 406. [Abstract] [Full Text] [PDF]

				C. T. M. Brekelmans, C. Seynaeve, M. Menke-Pluymers, H. T. Bruggenwirth, M. M. A. Tilanus-Linthorst, C. C. M. Bartels, M. Kriege, A. N. van Geel, C. M. G. Crepin, J. C. Blom, et al. Survival and prognostic factors in BRCA1-associated breast cancer Ann. Onc., March 1, 2006; 17(3): 391 - 400. [Abstract] [Full Text] [PDF]

				M. B. Barton, C. N. West, I.-L. A. Liu, E. L. Harris, S. J. Rolnick, J. G. Elmore, L. J. Herrinton, S. M. Greene, L. Nekhlyudov, S. W. Fletcher, et al. Complications Following Bilateral Prophylactic Mastectomy J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 61 - 66. [Abstract] [Full Text] [PDF]

				S. M. Miller, P. Roussi, M. B. Daly, J. S. Buzaglo, K. Sherman, A. K. Godwin, A. Balshem, and M. E. Atchison Enhanced Counseling for Women Undergoing BRCA1/2 Testing: Impact on Subsequent Decision Making About Risk Reduction Behaviors Health Educ Behav, October 1, 2005; 32(5): 654 - 667. [Abstract] [PDF]

				A. W. Kurian, M. A. Mills, M. Jaffee, B. M. Sigal, N. M. Chun, K. E. Kingham, L. C. Collins, K. W. Nowels, S. K. Plevritis, J. E. Garber, et al. Ductal Lavage of Fluid-Yielding and Non-Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1082 - 1089. [Abstract] [Full Text] [PDF]

				K. Armstrong, E. Micco, A. Carney, J. Stopfer, and M. Putt Racial Differences in the Use of BRCA1/2 Testing Among Women With a Family History of Breast or Ovarian Cancer JAMA, April 13, 2005; 293(14): 1729 - 1736. [Abstract] [Full Text] [PDF]

				L. C. Friedman and R. M. Kramer Reproductive Issues for Women With BRCA Mutations J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 83 - 86. [Abstract] [Full Text] [PDF]

				M. D. Schwartz, B. N. Peshkin, and C. Isaacs In Reply: J. Clin. Oncol., February 20, 2005; 23(6): 1331 - 1332. [Full Text] [PDF]

				B. N. Peshkin, C. Isaacs, C. Finch, S. Kent, and M. D. Schwartz Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians J. Clin. Oncol., December 1, 2003; 21(23): 4322 - 4328. [Abstract] [Full Text] [PDF]

				B. A. Mincey Genetics and the Management of Women at High Risk for Breast Cancer Oncologist, October 1, 2003; 8(5): 466 - 473. [Abstract] [Full Text] [PDF]